The Fed cut rates. Biotech didn't notice.

Biotechs are instead spending their time advancing the kind of smart science that will catch the eye of cash-rich pharmaceutical companies.

Market Watch • Dec 10, 2025

Biotech ETF (XBI) Hits New 52-Week High

XBI hits a 52-week high, climbing 85% from its low, as biotech gains momentum from AI adoption and favorable market trends.

Zacks Investment Research • Dec 5, 2025

3 Potential Mid-Cap Biotech Buyout Targets In 2026

The biotech sector began December with notable weakness, as both IBB and XBI ETFs declined over two percent during trading on Monday.  The sector has bounced back since. However, small biotech stocks have been on a huge run since mid-September, due primarily to a notable uptick in M&A activity across the industry. Numerous small and midcap biotech/biopharma stocks have been purchased for significant buyout premiums in recent months.

Seeking Alpha • Dec 3, 2025

Two Sector ETFs Are Quietly Outperforming the S&P 500 Without a Single AI Stock

Prognostications that the AI bubble is grossly overbought have been increasing.

24/7 Wall Street • Dec 2, 2025

Final Trades: FTAI, ETN, COWZ, XBI

The Investment Committee give you their top stocks to watch for the second half.

CNBC Television • Nov 26, 2025

Final Trades: Taiwan Semi, Apple and the XBI

The Investment Committee give you their top stocks to watch for the second half.

CNBC Television • Nov 24, 2025

Is State Street SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

The State Street SPDR S&P Biotech ETF (XBI) made its debut on 01/31/2006, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market.

Zacks Investment Research • Nov 19, 2025

Why biotech and drug stocks are on the mend even though the rest of the market is hurting

Drugmakers are making notable deals, biotech is coming back, and much of the worry about tariffs and interest rates has faded away.

Market Watch • Nov 18, 2025

Biotech Insiders Are Spending Billions. Trump Favors Less Oversight.

M&A activity is surging. Donald Trump's penchant for deregulation is boosting optimism.

The Motley Fool • Nov 18, 2025

3 Best Healthcare Stocks: Quant Strong Buys From Goldman's 'Alpha' List

The healthcare sector's renewed momentum offers fertile ground for investors wanting to outperform by picking the best stocks from the broader indexes. Goldman Sachs identified 29 healthcare stocks in the Russell 1000 universe with positive recent consensus revisions to 2026 EPS estimates and that trade at attractive valuations. Goldman sees "more opportunity for alpha than beta" as wide return dispersion and increasing M&A activity in healthcare may favor selected winners.

Seeking Alpha • Nov 17, 2025